GENOSTICS® AUSTRALIA PTY LTD

DATAR CANCER GENETICS UNITED KINGDOM | GERMANY | INDIA

1. PATIE	NT DETAILS:									
TITLE SU	RNAME		GIVEN NAM	ΛE		С	OOB (dd/mm/yy)		М	F
STREET ADDR	ESS		SUBURB			STA	TE/TOWN	POSTO		
PHONE (incl. a	rea code)		EMAIL							
	ESTING PHYS				2, 3, 4					
FULL NAME		Т	YPE OF PHYS	SICIAN		P	PROVIDE NUMBER			
EMAIL (REQUI	RED FOR REGISTRATIO	ON TO VIEW RES	ULTS)	CLINIC NAME						
CLINIC ADDRE	SS	s	SUBURB	l		;	STATE/TOWN			
POST CODE		PHONE (incl.ar	rea code)				FAX			
3. CLINIC	CAL INFORMA	TION ***mai	ndatory***							
PATIENT'S M	EDICAL DETAILS						dd/mr	n/yyyy		
Type of Cance	er:				Date of D)iagnos	sis:/			
						-		-·		
Surgery	Yes No If ye	es, when:		** If	yes, please send FF	PE blo	ck to DCGL (option	al)		
	available: Yes No notherapy: Yes No		stology/patho		//		dd/mm/yyyy			
Date of last ch	nemotherapy/_	/	Current rac	liation: Yes	No	Numb	er of Cycles			
Name of other	drugs:									
Date of last ra	diotherapy/_	/		t PET?CT/MRI /	//		dd/mm/yyyy			
Family History	r:				History of re-	cent blo	ood transfusion: Yes	S	No	
Other Medical	History:						ow transplant: Yes	5	No	
History of rece	ent blood transfusion: \	Yes No	lf y	yes, date	_//		dd/mm/yyyy			
Diabetes	Hypertension	CAD Hy	percholestero	olemia	Any other					
1) Smoking:	Yes No	If yes (years) _		4) Exposure to	radiation: Yes	No	lf yes (year	s)		
2) Alcohol:	Yes No	If yes (years)		5) Exposure to	UV rays: Yes	No	If yes (year	s)		
3) Vegetarian	:Yes No	If yes (years)_		6) A normal vita	amin level: Yes	No	If yes (year	s)		
					Vit D v	Vit B1	2 Vit B6			

4. TESTING

\$ 7800 AUD

EXACTA PLUSTM

Chemosensitivity, Repossesed drugs & botanicals

From DATAR CANCER GENETICS

exacta plus TM

- . analyses peripheral blood of the patient and/or freshly biopsied tissue FFPE Block In detail, cell-free DNA, exosomal mRNA, gene amplifications, tumor
- mutation load and heterogeneity are analysed
- Determines the most effective drugs/drug combinations on living tumor cells of the respective patient, if sufficient tumor material are present in the blood sample.
- · Plus chemosensitvities repurposed drugs & botanicals

From DATAR CANCER GENETICS exacta TM

\$ 7500 AUD

EXACTATM

- · analyses peripheral blood of the patient and/or freshly biopsied tissue FFPE Block In detail, cell-free DNA, exosomal mRNA, gene amplifications, tumor mutation load and heterogeneity are analysed
- Determines the most effective drugs/drug combinations on living tumor cells of the respective . patient, if sufficient tumor material are present or in the blood sample.

From DATAR CANCER GENETICS chemo-scale TM

- chemo-scaleTM is an analysis of tumour cells to provide drug efficacy and resistance guidance for chemotherapy, botanicals and repurposed drugs.
- With chemo-scaleTM analysis, we minimise the risks of therapy failure for the patient saving money, reducing 'trial and error' and most importantly, intensifying the attack on the patient's cancer, not the patient.
- chemo-scaleTM directly tests the effect of chemotherapy / anti-cancer drugs on the patient's tumour cells. It helps to customise the treatment plan according to sensitivity and resistance patterns of tumour cells.
- · When armed with this information, the physician and the patient can choose the most effective chemotherapy from the available options.
- chemo-scaleTM is perfomed on cells taken from a fresh biopsy sample of the tumour or circulating tumour associated cells (C-ETACs) isolated from peripheral blood. Analysing the chemosensitivity pattern of circulating tumour associated cells and tumour tissue derive cells of the same patient, we observed a concordance of 93.7%

\$ 3880 AUD

chemo-spale*

Chemosensitivity, repurposed drugs & botanicals

From DATAR CANCER GENETICS

- chemo-scaleTM is an analysis of tumour cells to provide drug efficacy and resistance guidance for botanicals and epurposed drug
- With chemo-scaleTM analysis, we minimise the risks of therapy failure for the patient saving money, reducing 'trial and error' and most importantly, intensifying the attack on the patient's cancer, not the patient.
- $chemo-scale TM\ directly\ tests\ the\ effect\ of\ chemotherapy\ /\ anti-cancer\ drugs\ on\ the\ patient's\ tumour\ cells.\ It\ helps\ to\ patient for\ the patient of\ the patient of\ the\ patient of\ the\ patient of\ the\ patient\ the\ pa$ customise the treatment plan according to sensitivity and resistance patterns of tumour cells.
- When armed with this information, the physician and the patient can choose the most effective chemotherapy from the available options
- chemo-scaleTM is performed on cells taken from a fresh biopsy sample of the tumour or circulating tumour associated cells (C-ETACs) isolated from peripheral blood. Analysing the chemosensitivity pattern of circulating tumour associated cells and tumour tissue derive cells of the same patient, we observed a concordance of 93.7%

\$ 3150 AUD

chemo-spale

Repurposed drugs & botanicals

\$ 2950 AUD

CANCERTRACK™

Blood based monitoring for all solid organ tumours

From DATAR CANCER GENETICS

cancertrack TM

- Multi-cordinate ad multidimensional probes to track down DNA released by cancer cells in patient's blood
- Unique, unprecentented capability to detect cancerous activity
- Real-time adjustment of the medication based on the test results
- Safe, sure, simple and cost effective
- Minimally invasive blood test
- Rapid lab result
- Tests all active disease sites
- Limit of detection is 0.1% Mutant Allele Frequency

\$3550 AUD

CELLDX_{TM}

Deep genomic analysis of solid *tumours*

From DATAR CANCER GENETICS
celldxTM provides molecular analysis for patients with advanced cancer.
SNV's |INDELS - 392 Genes
CNAs - 333 Genes
Fusions - 51 Genes
TMB | DU 1

TMB | PDL1 MSI | MMR

Testing for - NSCLC, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Melanoma, Urotheial Carcinoma, Gastric or GE junction adenocarcinoma, Pancreatic Cancer, Prostate Cancer Thyroid Cancer and solid Tumours

REQUIREMENTS FOR TESTING



ABSOLUTE IMPACT ABSOLUTE SCIENCE **ABSOLUTE COMMON SENSE**

chemo-spale



- Completed Request Form
- Copy of Histopathology Report (if sending a solid biopsy)
- Consent Letter for Release of Specimen (page 4) (if sending a solid biopsy)
- 1. Fax (+61 2 8088 7097) or email (admin@genostics.com.au) the documents listed above
- cancertraok
- 2. Genostics procures the solid biopsy Genostics ships the solid biopsy/liquid biopsy directly to Datar Cancer Genetics.
- Or Genostics sends the kit to the patient to complete the liquid biopsy and the patient ships the kit directly to Datar Cancer Genetics.

5. TERMS AND CONDITIONS:

Please ensure that you have discussed the following with your Health Practitioner before proceeding with a test request:

- i) your medical condition in relation to the test/s you are requesting;
- ii) an explanation of the test/s requested on this test request form;
- iii) the purpose and benefit of the test/s requested on this test request form.
- iv) You confirm that you have had adequate time to fully understand the nature of the test/s chosen, the associated costs, and the terms as set out on this test request form.

You confirm that you are of sound mind and over 18 years of age – if the person undertaking the test/s requested on this test request form is a minor, then consent must be provided by a parent or legal guardian.

6. PAYMENT and CANCELLATION POLICY:

Payment will be processed prior to shipment of a kit; this includes shipment from either Genostics to Datar Cancer Genetics or shipment from Genostics to the nominated recipient for either EXACTA OR CHEMOSCALE testing.

There will be no cancellation after payment has been processed and a kit shipped, unless the specimen block and/or liquid biopsy does not passQC standards as performed by DATAR CANCER GENETICS.

If a sample does not pass QC as performed by DATAR CANCER GENETICS, a fee of AUD \$350.00 will be charged for shipment and processing of sample(s).

7. DISCLAIMER/LIABILITY EXCLUSION:

The tests (described in this form) facilitated by Genostics do not replace currently recommended methods of cancer detection and screening. Test results do not constitute a diagnosis of disease or condition. The tests and results do not offer conclusive and consistent solutions to cancer diagnoses and treatment. Each individual is unique. Test results can only aid diagnosis, detection, monitoring and cancer treatment decisions (including targeted therapy), within the context of clinical assessment and standard screening tests.

Do not use the content of this document, test results or related information to dispense with or disregard any medical advice, nor to delay seeking medical advice. A patient should always consult his/ her health/medical practitioner to determine the appropriateness of test(s) for his/her case or if he/she has any questions regarding a medical condition or treatment plan. The interpretation of any test and clinical management of he relevant patient's condition is the responsibility of the treating health/medical practitioner.

This document and its content do not create a health/medical practitioner-patient relationship. Genostics does not offer any medical advice. Genostics does not engage in medical practice.

Genostics gives no and can give no warranties or guarantees (expressed or implied, statutory or otherwise) concerning the test(s), whet regards (1) procedures or quality, (2) technical, functional and other specifications, (3) test results, or (4) information or advice obtained pursuant to this document or test results.

- 8. CONSENT: By signing this request form, I the person undertaking the test/s, or the parent/legal guardian:
- i) Give my consent to Genostics to facilitate the test/s & services requested on this test request form, the acquisition and supply of the appropriate tissue specimen to DATAR CANCER GENETICS for the testing requested as per this request form, the electronic release and delivery of test results, and the collection of my personal data for research purposes;
- ii) Give my consent to DATAR CANCER GENETICS to use my specimen sample(s) for medical testing and analysis, as per this request form, the electronic release and delivery of test results, and I relinquish any claim of ownership of the sample(s) or any of its components;
- iii) Give my consent to DATAR CANCER GENETICS and GENOSTICS to use my specimen sample(s) for medical research development and the collection of data for statistical analysis;

I also confirm that I understand, consent to and agree to all terms in or referenced in this test request including the cancellation policy, data use and privacy terms, price and payment terms and the disclaimer and liability exclusions

I hereby give my consent for Genostics to share the results with the patient listed herein and/or any other authorised third party

9.PRACTITIONER SIGNATUI	RE	DATE(dd/mm/yy)//			
10.PATIENT SIGNATURE:		DATE(<i>dd/mm/yy</i>)//_			
6. PAYMENT:- VISA OR MA	ASTERCARD ONLY				
CREDIT CARD NUMBER		(mm/yy) /			
CARDHOLDERS NAME: (as it appears on the card)	CARDHOLDERS SIGNATURE	\$			

CONSENT TO RELEASE SPECIMEN (IF REQUIRED)

Date: / mn	уу уу			
Patient First Nam	9	Patient Last Name		
Address				
Phone Number				
request and conse	nfirm that I, ent to the release o		tissue specimen	(first name, last name) from biopsy, performed
Surgery performed The biopsy is to be	d ate e sent for further a	analysis with DATAR (enostics Pty Ltd. Austra	 CANCER GENET	
Please note: sam	oles will be returne	d to the issuing labora	tory following con	npletion of testing.
Please send the	block to the follow	wing address:		
Genostics Pty Ltd				
1/63 Compass Dr Biggera Waters Q Australia Ph: +61 1300 282	LD, 4216			
Should you have	any questions, plea	ase do not hesitate to	contact me or Ge	nostics Pty Ltd.
Sincerely				
(print name)				
(signature)		_		